Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Source: SeekingAlpha
2025-12-10 13:43:43 ET
More on Dyne Therapeutics, Avidity Biosciences
- Dyne Therapeutics: Why The $350M Public Offering Was Critical
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy - Slideshow
- Dyne Therapeutics prices $350 stock offering
- Dyne Therapeutics announces $300M proposed public offering
Read the full article on Seeking Alpha
For further details see:
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Novartis AG
NASDAQ: NVS
NVS Trading
0.14% G/L:
$143.57 Last:
367,989 Volume:
$142.47 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
